title: Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.
abstract: The relationship between the oral efficacy and the acute toxicity of hydroxypyridin-4-one iron chelators has been investigated to clarify structure-function relationships of these compounds in vivo and to identify compounds with the maximum therapeutic safety margin. By comparing 59Fe excretion following oral or intraperitoneal administration of increasing doses of each chelator to iron-overloaded mice, the most effective compounds have been identified. These have partition coefficients (Kpart) above 0.3 in the iron-free form with a trend of increasing oral efficacy with increasing Kpart values (r = .6). However, this is achieved at a cost of increasing acute toxicity, as shown by a linear correlation between 59Fe excretion increase per unit dose and 1/LD50 (r = .83). A sharp increase in the LD50 values is observed for compounds with Kpart values above 1.0, suggesting that such compounds are unlikely to possess a sufficient therapeutic safety margin. Below a Kpart of 1.0, acute toxicity is relatively independent of lipid solubility. All the compounds are less toxic by the oral route than by the intraperitoneal route, although iron excretion is not significantly different by these two routes. At least five compounds (CP51, CP94, CP93, CP96, and CP21) are more effective orally than the same dose of intraperitoneal desferrioxamine (DFO) (P less than or equal to .02) or orally administered L1(CP20) (P less than or equal to .02).
authors: Department of Clinical Haematology, University College and Middlesex School of Medicine, London, UK.
authors: J B
authors: JB
authors: Porter
authors: J
authors: J
authors: Morgan
authors: K P
authors: KP
authors: Hoyes
authors: L C
authors: LC
authors: Burke
authors: E R
authors: ER
authors: Huehns
authors: R C
authors: RC
authors: Hider
mesh_terms: D000284:Administration, Oral; D000818:Animals; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000737:chemistry; D007274:Injections, Intraperitoneal; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D007504:Iron Radioisotopes / Q000378:metabolism / Q000652:urine; D007700:Kinetics; D007928:Lethal Dose 50; D008055:Lipids; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D012995:Solubility; D013329:Structure-Activity Relationship
chemical_list: D007502:Iron Chelating Agents; D007504:Iron Radioisotopes; D008055:Lipids; D011728:Pyridones